Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
120M
-
Number of holders
-
53
-
Total 13F shares, excl. options
-
17.4M
-
Shares change
-
+3.34M
-
Total reported value, excl. options
-
$101M
-
Value change
-
+$20.6M
-
Number of buys
-
35
-
Number of sells
-
-16
-
Price
-
$5.82
Significant Holders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) as of Q4 2019
59 filings reported holding AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value as of Q4 2019.
Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) has 53 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.4M shares
of 120M outstanding shares and own 14.5% of the company stock.
Largest 10 shareholders include Bratton Capital Management, L.P. (11.5M shares), Opaleye Management Inc. (739K shares), VANGUARD GROUP INC (592K shares), Wildcat Capital Management, LLC (455K shares), Bracebridge Capital, LLC (429K shares), MILLENNIUM MANAGEMENT LLC (362K shares), Eversept Partners, LP (350K shares), JPMORGAN CHASE & CO (319K shares), OXFORD ASSET MANAGEMENT LLP (312K shares), and D. E. Shaw & Co., Inc. (263K shares).
This table shows the top 53 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.